Recon: Teva Settles Oklahoma Opioid Suit for $85M; FDA Approves Allergan's Vraylar for Bipolar Depression

Recon: Teva Settles Oklahoma Opioid Suit for $85M; FDA Approves Allergan's Vraylar for Bipolar Depression - Regulatory Focus

May 30, 2019

Recon: Teva Settles Oklahoma Opioid Suit for $85M; FDA Approves Allergan's Vraylar for Bipolar Depression Regulatory Focus

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. Teva reaches $85 million settlement on eve of ...

Poliomyelitis Treatment

Recon: Teva Settles Oklahoma Opioid Suit for $85M; FDA Approves Allergan's Vraylar for Bipolar Depression - Regulatory Focus

Comments

Post a Comment

Popular posts from this blog

Glimpse of the Past: Polio epidemic in 1940s-1950s affected Mankato residents - Mankato Free Press

Schools prepare families for loss of philosophical, personal exemption for MMR vaccine - The Daily World

Glimpse of the Past: Polio epidemic in 1940s-1950s affected Mankato residents - Mankato Free Press